China BioMed Innovation and Investment Conference (CBIIC) was established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA) in 2016. As an annual grand conference to promote the communication between pharmaceutical industry and investment industry, CBIIC aims to integrate the power of pharmaceutical innovation and investment at home and abroad to build an authorized, comprehensive, professional and international high level platform where the industry leaders, experts, scholars, domestic and foreign pharmaceutical innovation enterprises and investors can learn the trend of innovation, seek high value projects and discuss new investment channels and innovative cooperation strategies to facilitate the timely transformation of unmet clinical needs, promote the pharmaceutical innovation and serve the public health.
During the meeting NMS group's CEO made a presentation with the title “NMS Group - The World's Leading R&D Institution for Innovative Drugs”. He gave an ovierview about NMS group.
As a leading company in the world of innovative drug research and development, the NMS group will strive to become a leader in drug innovation in China and in benevolent competition on the market and to help improve patient health in China and world through a new business and development model.